Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1995 2
1997 1
1998 2
1999 1
2000 4
2001 2
2002 3
2003 1
2004 1
2005 2
2006 2
2007 1
2016 1
2019 1
2023 2
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts.
Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Cole J, Bafadhel M, Christenson SA, Papi A, Singh D, Laws E, Mannent LP, Patel N, Staudinger HW, Yancopoulos GD, Mortensen ER, Akinlade B, Maloney J, Lu X, Bauer D, Bansal A, Robinson LB, Abdulai RM; BOREAS Investigators. Bhatt SP, et al. N Engl J Med. 2023 Jul 20;389(3):205-214. doi: 10.1056/NEJMoa2303951. Epub 2023 May 21. N Engl J Med. 2023. PMID: 37272521 Clinical Trial.
Short- and long-term effects of imatinib in hospitalized COVID-19 patients: A randomized trial.
Halme ALE, Laakkonen S, Rutanen J, Nevalainen OPO, Sinisalo M, Horstia S, Mustonen JMJ, Pourjamal N, Vanhanen A; Solidarity Finland Investigators; Rosberg T, Renner A, Perola M, Paukkeri EL, Patovirta RL, Parkkila S, Paajanen J, Nykänen T, Mäntylä J, Myllärniemi M, Mattila T, Leinonen MK, Külmäsu A, Kuutti P, Kuitunen I, Kreivi HR, Kilpeläinen TP, Kauma H, Kalliala IEJ, Järvinen P, Hankkio R, Hammarén T, Feuth T, Ansakorpi H, Ala-Karvia R, Guyatt GH, Tikkinen KAO. Halme ALE, et al. J Infect. 2024 Sep;89(3):106217. doi: 10.1016/j.jinf.2024.106217. Epub 2024 Jul 3. J Infect. 2024. PMID: 38969238 Free article. Clinical Trial.
[Neurofibromin].
Ylä-Outinen H, Peltonen J. Ylä-Outinen H, et al. Duodecim. 1993;109(5):376-9. Duodecim. 1993. PMID: 8020402 Review. Finnish. No abstract available.
Upregulation of tumor suppressor protein neurofibromin in normal human wound healing and in vitro evidence for platelet derived growth factor (PDGF) and transforming growth factor-beta1 (TGF-beta1) elicited increase in neurofibromin mRNA steady-state levels in dermal fibroblasts.
Ylä-Outinen H, Aaltonen V, Björkstrand AS, Hirvonen O, Lakkakorpi J, Vähä-Kreula M, Laato M, Peltonen J. Ylä-Outinen H, et al. J Invest Dermatol. 1998 Mar;110(3):232-7. doi: 10.1046/j.1523-1747.1998.00108.x. J Invest Dermatol. 1998. PMID: 9506441 Free article. Review.
New function for NF1 tumor suppressor.
Koivunen J, Ylä-Outinen H, Korkiamäki T, Karvonen SL, Pöyhönen M, Laato M, Karvonen J, Peltonen S, Peltonen J. Koivunen J, et al. Among authors: yla outinen h. J Invest Dermatol. 2000 Mar;114(3):473-9. doi: 10.1046/j.1523-1747.2000.00882.x. J Invest Dermatol. 2000. PMID: 10692105 Free article.
Distinctive Cancer Associations in Patients With Neurofibromatosis Type 1.
Uusitalo E, Rantanen M, Kallionpää RA, Pöyhönen M, Leppävirta J, Ylä-Outinen H, Riccardi VM, Pukkala E, Pitkäniemi J, Peltonen S, Peltonen J. Uusitalo E, et al. Among authors: yla outinen h. J Clin Oncol. 2016 Jun 10;34(17):1978-86. doi: 10.1200/JCO.2015.65.3576. Epub 2016 Feb 29. J Clin Oncol. 2016. PMID: 26926675
27 results